跳至主要内容
临床试验/NCT06327646
NCT06327646进行中(未招募)不适用

Non-inferiority Assessment of Maternal Adherence to Supplementation: a Trial on the Effects of MMS

Helen Keller International118 个研究点 分布在 1 个国家目标入组 2,640 人开始时间: 2024年7月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
2,640
试验地点
118
主要终点
Pregnancy supplementation for 180 days: binary

研究概览

简要总结

Although clinical studies highlight the value of MMS for pregnant and lactating women, implementation research studies are necessary to understand adherence and acceptability to the product and to uncover potential obstacles to implementation in specific contexts. For Nepal, it is crucial to establish whether adherence to MMS supplementation is non-inferior to the existing IFA supplementation for 180 tablets, which has a high (65%) adherence rate. It is also important to investigate how whether providing MMS in bottles (containing a substantial quantity, such as 90 count bottles twice during pregnancy) might impact ANC utilization, particularly in terms of ensuring that pregnant women attend at least eight ANC visits. Furthermore, assessment of MMS acceptability, including pill taste, smell, size, swallowability, side effects, benefits as well as aspects such as product labeling and packaging, among end users in Nepal, is needed to understand acceptability of MMS vs. IFA. Finally, implementation issues within the health system, including the need of trainings for healthcare workers' and, female community health volunteers (FCHVs)' training needs; and government stakeholders' interest and barriers;; community s Social and behavioral change communication needs, and issues around supply chain issues should be well-understood and documented to inform prior to scale-up to support a smooth transition of MMS. Thus, Helen Keller International, in collaboration with Nepal's Ministry of Health and Population (MoHP) and the Eleanor Crook Foundation (ECF), will conduct a set of four mixed-methods studies to generate evidence and insights that inform the development of an MMS supplementation strategy. This trial in one province of Nepal is the first study that will be complemented by one additional quantitative study and two qualitative studies to generate evidence on the topics mentioned.

详细描述

The primary and secondary research questions for the randomized controlled trial named "Non-inferiority Assessment of Maternal Adherence to Supplementation: A Trial of the Effects of MMS" (NAMASTE MMS) are detailed below:

Primary:

  1. Is adherence to the full prescription of 180 MMS (-blister) during pregnancy non-inferior to adherence to the full prescription of 180 IFA-blister during pregnancy (arm 2 vs arm 1)?
  2. Is adherence to the full prescription of 180 MMS (-bottle) during pregnancy non-inferior to adherence to the full prescription of 180 IFA-blister during pregnancy (arm 3 vs arm 1)?

Secondary:

  1. Is the level of adherence to MMS-blister and MMS-bottle non-inferior to the level of adherence to IFA-blister at different points during pregnancy and lactation (i.e. 30 days, 90 days, and 45 days postpartum from start of supplementation) (arm 2 vs. arm 1 and arm 3 vs arm 1)?
  2. Is there a difference in adherence to 180 MMS during pregnancy from blister packaging vs bottle packaging of MMS (arm 2 vs arm 3?
  3. Is there a difference in adherence to ANC visits during pregnancy from blister packaging vs bottle packaging of MMS (arm 2 vs arm 3)?
  4. What is the level of acceptability of IFA and MMS at different stages of pregnancy (i.e. 30 days, 90 days, 180 days, and 45 days postpartum) (arms 1, 2 and 3)?
  5. What is the validity of women's recall of the amount of MMS/IFA received and of adherence to MMS/IFA compared to a gold standard?

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

IFA-180 (Blister)

Active Comparator

干预措施: Iron Folic Acid Blister (Drug)

MMS-180 (Blister)

Experimental

干预措施: Multiple Micronutrient Supplement Blister (Drug)

MMS-180 (Bottle)

Experimental

干预措施: Multiple Micronutrient Supplement Bottle (Drug)

结局指标

主要结局

Pregnancy supplementation for 180 days: binary

时间窗: Delivery

Consumed at least 180 supplement tablets between study enrollment and delivery (MMS-blister vs IFA-blister; MMS-bottle vs. IFA blister)

Pregnancy supplementation for 180 days: continuous

时间窗: Delivery

Number of supplements consumed between study enrollment and delivery (MMS-blister vs IFA-blister; MMS-bottle vs. IFA blister)

次要结局

  • MMS supplementation for 180 days: continuous(Delivery)
  • Full pregnancy supplementation: binary(Delivery)
  • MMS supplementation for 180 days: Binary(Delivery)
  • Full pregnancy supplementation: continuous(Delivery)
  • Antenatal Care Utilization: continuous(Delivery)
  • Antenatal Care Utilization: binary(Delivery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kenda Cunningham

Sr. Research Advisor

Helen Keller International

研究点 (118)

Loading locations...

相似试验